ROS1 and non-small cell lung carcinoma: This is the first large-scale retrospective study to comprehensively investigate the efficacy of crizotinib, pemetrexed-based and non-pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 fusion-positive.